Experimental nasal drops may prevent Alzheimer’s memory loss, scientists say

Scientists have developed experimental nasal drops that could enhance memory and prevent cognitive decline in aged mice, an advance that may lead to new treatments for Alzheimer’s disease.

The experimental treatment uses mRNA technology similar to that developed for use in Covid-19 vaccines, say researchers at the University of Sydney.

Researchers found that the mRNA drug packaged in fat nanoparticles could turn the nose into a drug factory.

One of the main challenges in developing drugs for Alzheimer’s and other neurological conditions is delivering therapies across the blood-brain barrier – the protective barrier blocking many drugs from entering the brain.

But nasal delivery has been shown to exploit connections between the nasal cavity and the brain, enabling direct access to the nervous system without invasive surgery or injections.

Once the mRNA molecules enter nasal cells, it could make them produce medically active proteins that can enter the brain and increase cognitive ability, scientists explained.

“In aged mice, we saw learning and memory significantly increased, returning animal cognition to its youthful prime,” Greg Neely, an author of the study published in the journal Advanced Science.

“This approach could represent a world-first non-invasive delivery system to treat Alzheimer’s that bypasses the blood-brain barrier,” Dr Neely said.

In the study, scientists induced nasal cells to produce brain-derived neurotrophic factor (BDNF), a naturally occurring protein that supports neuron survival and memory formation.

Previous studies have shown that reduced BDNF levels are associated with ageing and Alzheimer’s disease.

Aged mice showed a decline in cognitive ability, but those treated with the nasal drops performed similarly to young mice in a series of behavioural tests assessing working memory, spatial memory and object recognition.

Scientists also tested the treatment in mice carrying genetic mutations that serve as an animal model of Alzheimer’s disease.

Dr Maria Bergamasco in the Dr John and Anne Chong Lab for Functional Genomics
Dr Maria Bergamasco in the Dr John and Anne Chong Lab for Functional Genomics (Stefanie Zingsheim/The Universty of Sydney)

Such mice given the BDNF nose drops when Alzheimer’s-like symptoms started manifesting were protected against the severe cognitive decline normally seen in the model.

These mouse models typically have Alzheimer’s disease brain pathologies detectable from two months, with cognitive decline apparent from four months of age.

Researchers regularly treated the animals with the mRNA delivery system twice a week from two months of age, and found that at four months, the mice showed no cognitive decline.

The treatment appeared to preserve brain function without reducing amyloid plaques, the hallmark protein clumps associated with Alzheimer’s disease.

This suggests that the treatment approach could complement, rather than replace, existing Alzheimer’s therapies.

“Just under a third of Alzheimer’s patients have serious plaques but do not suffer from dementia, and these patients show naturally higher BDNF levels, suggesting that if we raise BDNF, it’s possible to live with Alzheimer’s disease pathology,” Dr Neely said.

“Our approach seems to work not by clearing plaques but by supporting the health, survival and connectivity of neurons themselves. It raises the possibility these therapies could eventually work alongside each other,” he said.

Scientists caution that the research remains at the preclinical stage and that mouse studies are an essential early step before any potential human trials.

“It is a very promising pathway, but human noses are different from mouse noses, so we will need to test our drugs in humans before we know whether it will work,” Dr Neely said.

“We believe our new drug, if it works in humans, can promote general cognitive health as people age, should help treat a variety of neurodegenerative diseases, and may even increase cognitive abilities in healthy young people,” he said.